Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Inhibitors

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search
Image of 2D Structure
Search for synonyms (with exact matching search term)

Search term:

Results 1 - 10 of 35 > >>
download as CSV
download all results as CSV
EC Number Inhibitors Commentary Structure
Display the word mapDisplay the reaction diagram Show all sequences 3.4.21.B60(3R)-1-[(3-[(1R)-1-amino-2-[(3S,4R)-1-[[4-(aminomethyl)phenyl]methyl]-4-methylpyrrolidin-3-yl]ethyl]phenyl)methyl]piperidin-3-ol inhibitor developed by fragment-based drug design Go to the Ligand Summary Page
Display the word mapDisplay the reaction diagram Show all sequences 3.4.21.B60(3R,4R)-1-[[4-(aminomethyl)phenyl]methyl]-4-(2-[(1R,2Z)-2-[(5-hydroxy-2-methoxyphenyl)methylidene]cyclobutyl]ethyl)pyrrolidin-3-ol inhibitor developed by fragment-based drug design Go to the Ligand Summary Page
Display the word mapDisplay the reaction diagram Show all sequences 3.4.21.B60(3S)-1-[(3-[(1S)-1-amino-3-[(3S,4R)-1-[[4-(aminomethyl)phenyl]methyl]-4-methylpyrrolidin-3-yl]propyl]phenyl)methyl]piperidin-3-ol inhibitor developed by fragment-based drug design Go to the Ligand Summary Page
Display the word mapDisplay the reaction diagram Show all sequences 3.4.21.B60(3S)-3-(aminomethyl)-5-[(3R,4S)-1-[[4-(aminomethyl)phenyl]methyl]-4-methylpyrrolidin-3-yl]-1-(3,4-dihydroisoquinolin-2(1H)-yl)pentan-1-one inhibitor developed by fragment-based drug design Go to the Ligand Summary Page
Display the word mapDisplay the reaction diagram Show all sequences 3.4.21.B60(3S)-4-[(3R)-3-amino-3-(4-[[(3S)-3-hydroxypyrrolidin-1-yl]methyl]phenyl)propyl]-1-[[4-(aminomethyl)phenyl]methyl]pyrrolidin-3-ol inhibitor developed by fragment-based drug design Go to the Ligand Summary Page
Display the word mapDisplay the reaction diagram Show all sequences 3.4.21.B60(4S)-4-amino-5-[(3R,4S)-1-[[4-(aminomethyl)phenyl]methyl]-4-hydroxypyrrolidin-3-yl]-1-(1,4-dihydro-3H-2,3-benzoxazin-3-yl)pentan-1-one inhibitor developed by fragment-based drug design Go to the Ligand Summary Page
Display the word mapDisplay the reaction diagram Show all sequences 3.4.21.B60(4S)-4-amino-7-[(3R,4R)-1-[[4-(aminomethyl)phenyl]methyl]-4-hydroxypyrrolidin-3-yl]-1-(1,4-dihydro-3H-2,3-benzoxazin-3-yl)heptan-1-one inhibitor developed by fragment-based drug design Go to the Ligand Summary Page
Display the word mapDisplay the reaction diagram Show all sequences 3.4.21.B6010-hydroxyusambarensine binding energy -10.4 kcal/mol, additionally binds to ACE2 and SARS-CoV-2 spike protein Go to the Ligand Summary Page
Display the word mapDisplay the reaction diagram Show all sequences 3.4.21.B602,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-amine compound exhibits a nearly effective TMPRSS2 inhibitory activity relative to tafenoquine , while it is deficient in SARS-CoV-2 main protease inhibition Go to the Ligand Summary Page
Display the word mapDisplay the reaction diagram Show all sequences 3.4.21.B603-[(Z)-[(2R,3R)-3-amino-2-[3-[(3S)-1-[[4-(aminomethyl)phenyl]methyl]pyrrolidin-3-yl]propyl]cyclobutylidene]methyl]-4-methoxyphenol inhibitor developed by fragment-based drug design Go to the Ligand Summary Page
Results 1 - 10 of 35 > >>
download as CSV
download all results as CSV